Background The purpose of this scholarly study was to measure the ramifications of darapladib, a selective oral investigational lipoprotein-associated phospholipase A2 inhibitor, on both plaque and plasma lipoprotein-associated phospholipase A2 activity. placebo). Within a post-hoc evaluation, plaque caspase-3 (P